
Go here, and you'll find Medgadget's Wiki---who knew!
I ran into this by accident in a Google search.

Some years ago a number of analysts observed there was a pattern of new technology," says Laura Behrens, analyst at Gartner. "Something new would happen, there would be tremendous excitement, followed by disillusionment. Then some of those would eventually become well understood in their markets. "This happened with such regularity that they could do this model."
On a curve of development, the Hype Cycle tries to predict where technologies are heading: into our pockets and living rooms, or into the Betamax graveyard.
It starts with the "technology trigger", where a breakthrough or event generates publicity, exposing the gadget or technology to a wider audience. This is not a Middle Earth battle ground; it is where technology goes to wilt when it fails to deliver its promises. As people start to learn more about the technology, it starts to struggle up the slope of enlightenment. The final stage is the "plateau of productivity" when it becomes mainstream.

Invention to Venture: Affordable Technology
one the panels in the afternoon (about Aerovax, opportunities at BOP, and how to convey that to investors), along with Chuck Lacy, President of Vermont-based Barred Rock Fund and former President of Ben and Jerry's.Workshop Details:
Conference Co-Chairs: Iqbal Quadir and Sandy Pentland
Date: Saturday, May 5, 2007 Time: 9:30 a.m. – 3:30 p.m. Location: Stata Center (32-155), MIT. The Stata is the weird building in case you don't know where to go.
Mention Aerovax at the entrance and you get a free inhalables measles shot, cherry and orange flavors upon request.
I think this will be fun...there's lots of panels. It will add the my backlog of entries for LTDC.There is also some cool stuff going on this week---
part of EUREKA FEST.
Hopefully I'll see some you there. Okay, I was kidding about the measles, but you can learn more about it anyways.
Beyond Traditional Borders encourages students to transcend geographic and disciplinary boundaries to understand, address and solve health problems in the developing world through the design and implementation of new appropriate health technologies.Perhaps anyone out there will take some notes for us, sounds like a great event.


Currently, GMD occupies an industry of one, but there is plenty of room for other generic manufacturers. Ideally, each new generic manufacturer would focus on a unique device segment in order to best meet increasing demand and maintain the highest levels of safety and efficacy.
